Literature DB >> 23389873

The appropriate treatment of chronic pain.

Piercarlo Sarzi-Puttini1, Renato Vellucci, Stefano Maria Zuccaro, Paolo Cherubino, Roberto Labianca, Diego Fornasari.   

Abstract

Chronic pain is a common healthcare problem worldwide that ranks as a predominant reason for consulting a physician, yet effective management of chronic pain remains suboptimal, often resulting in unnecessary suffering and decreased quality of life, lost productivity and excessive healthcare costs. To overcome the challenges associated with the management of chronic pain, increased awareness and both patient and physician education are required. Improving physician knowledge of pain assessment and management guided by recommendations for a comprehensive, multifactorial, personalised treatment approach involving pharmacological and non-pharmacological approaches is key to achieving effective pain relief. Guidelines for the management of non-cancer and cancer pain recommend thorough patient assessment before individualized therapy based on the type and intensity of pain. The availability of mechanism-specific analgesics has facilitated improvements in the treatment of chronic non-cancer pain, which may be of neuropathic, muscle, inflammatory, mechanical/compressive or mixed origin. Stepwise escalation of analgesic therapy (paracetamol, non-steroidal anti-inflammatory drugs, mild to strong opioids) according to the World Health Organization's three-step pain ladder remains the standard approach for the selection of treatment for chronic cancer pain, although there is now a greater awareness of the requirements for effective administration of opioids including dose titration, use of short versus long-acting opioids, opioid rotation, management of adverse effects, and ongoing monitoring. Selection of an effective, appropriate, personalized analgesic regimen for patients with chronic pain is achievable and is expected to enhance compliance, overall functioning and quality of life.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23389873     DOI: 10.2165/11630050-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  4 in total

1.  Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study.

Authors:  Jordi Barrachina; Cesar Margarit; Javier Muriel; Santiago López-Gil; Vicente López-Gil; Amaya Vara-González; Beatriz Planelles; María-Del-Mar Inda; Domingo Morales; Ana M Peiró
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

2.  Expression of ectopic heat shock protein 90 in male and female primary afferent nociceptors regulates inflammatory pain.

Authors:  Yaomin Wang; Scott A Scarneo; Shin Hyung Kim; Xin Zhang; Jiegen Chen; Kelly W Yang; Philip Hughes; Timothy Haystead; Andrea G Nackley
Journal:  Pain       Date:  2021-10-12       Impact factor: 7.926

Review 3.  Neuronal and glial factors contributing to sex differences in opioid modulation of pain.

Authors:  Dayna L Averitt; Lori N Eidson; Hillary H Doyle; Anne Z Murphy
Journal:  Neuropsychopharmacology       Date:  2018-06-23       Impact factor: 7.853

Review 4.  Reward Circuitry Plasticity in Pain Perception and Modulation.

Authors:  Marcos F DosSantos; Brenda de Souza Moura; Alexandre F DaSilva
Journal:  Front Pharmacol       Date:  2017-11-21       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.